Answers are grounded in this paper and cite their sources.
Article, see p 2330 C lassically, atherosclerosis has been considered a systemic process. 1 A history of an atherosclerotic event in 1 vascular bed is typically the largest risk marker for events in other vascular territories, further supporting a shared pathophysiology. 2 However, studies of risk for atherosclerotic events have largely been driven by the dominance of coronary and cerebrovascular disease.Only ≈5% of the international REACH registry (Reduction of Atherothrombosis for Continued Health) of patients with a history of atherosclerotic disease had isolated peripheral artery disease (PAD) as their qualifying phenotype.1 In contrast, a majority of REACH participants with PAD also had concomitant coronary or cerebrovascular disease.This overlap of atherosclerotic phenotypes has led to a relative paucity of data to tease out any unique risk factors for incident PAD.In general, there is a stronger association of PAD with smoking compared with coronary artery disease, followed by similar associations of PAD with diabetes mellitus and more modest associations with hypertension and dyslipidemia.3,4 Biologically, the retention of apolipoprotein (apo) B-containing lipoproteins [very-low-density lipoprotein, intermediate-density lipoprotein, low-density lipoprotein (LDL), lipoprotein(a)] in the subendothelial space is a critical step in propagating atherosclerosis.5 Clinically, LDL cholesterol (LDL-C) is the most commonly used surrogate of the circulating burden of apo B-containing particles because historically LDL particles represented the vast majority of circulating lipoproteins.Reduction of LDL-C through removal of LDL particles by upregulation of the LDL receptor in hepatocytes is the principal measure of efficacy for pharmacotherapies shown to reduce atherosclerotic risk (particularly coronary atherosclerotic events), primarily with statins and now ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.6 Because of the variation in sizes of lipoproteins and their cholesterol content, several studies suggest that measures of particle burden, whether by particle concentrations or apo B levels, are generally more accurate markers of lipid-related cardiovascular disease risk than cholesterol concentrations.7,8 However, these measures have not demonstrated sufficient clinical utility to change current guideline recommendations for routine widespread use.9 In this issue, Aday et al 10 address a key knowledge gap in PAD risk while suggesting the possibility of alternative lipid-related biology in peripheral atherogenesis compared with coronary or cerebrovascular atherosclerosis.They capitalize on the robust longitudinal observational sample from the WHS (Women's Health Study) of nearly 28 000 female US healthcare professionals with advanced lipoprotein particle measures by nuclear magnetic resonance spectroscopy.Over the 15-year follow-up, incident PAD events, defined as intermittent claudication or peripheral revascularization, were collected and adjudicated by chart review with in-
No takes yet. Share an insight, caveat, or question.
Joshi et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: